Within this prospective study, we identified potential biomarkers (expression of CD5 for EFS and expression of FOXP1 for OS) that were able to predict the course of DLBCL at diagnosis, independent of stage and IPI. The gene discussed is FOXP1; the disease is diffuse large B-cell lymphoma.